Progressive Supranuclear Palsy clinical trials at UCSD
5 in progress, 2 open to eligible people
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
open to eligible people ages 18 years and up
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
San Diego, California and other locations
Automated Imaging Differentiation of Parkinsonism
open to eligible people ages 40-80
The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis.
La Jolla, California and other locations
TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
Sorry, in progress, not accepting new patients
This is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP.
La Jolla, California and other locations
Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
Sorry, in progress, not accepting new patients
This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.
La Jolla, California and other locations
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
Sorry, in progress, not accepting new patients
The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.
San Diego, California and other locations
Our lead scientists for Progressive Supranuclear Palsy research studies include Doug Galasko, MD Gabriel Leger, MD Irene Litvan, MD Ece Bayram,, MD, PhD.
Last updated: